Dr. Susan E. Bates
Claim this profileJames J Peters VA Medical Center
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
9 reported clinical trials
20 drugs studied
Area of expertise
1Lung Cancer
Stage II
Stage I
Stage III
2Non-Small Cell Lung Cancer
Stage IV
Stage III
Stage I
Affiliated Hospitals
Clinical Trials Susan E. Bates is currently running
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Peposertib + Avelumab + Radiation
for Hepatobiliary Cancer
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.
Recruiting1 award Phase 1 & 210 criteria
More about Susan E. Bates
Clinical Trial Related5 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Susan E. Bates has experience with
- Gemcitabine
- Pembrolizumab
- Pemetrexed
- Nab-paclitaxel
- Cisplatin
- Gemcitabine Hydrochloride
Breakdown of trials Susan E. Bates has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Bile Duct Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Susan E. Bates specialize in?
Susan E. Bates focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage II patients, or patients who are Stage I.
Is Susan E. Bates currently recruiting for clinical trials?
Yes, Susan E. Bates is currently recruiting for 4 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Susan E. Bates has studied deeply?
Yes, Susan E. Bates has studied treatments such as Gemcitabine, Pembrolizumab, Pemetrexed.
What is the best way to schedule an appointment with Susan E. Bates?
Apply for one of the trials that Susan E. Bates is conducting.
What is the office address of Susan E. Bates?
The office of Susan E. Bates is located at: James J Peters VA Medical Center, Bronx, New York 10468 United States. This is the address for their practice at the James J Peters VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.